In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer. (2021)

First Author: Malla SB
Attributed to:  MRC Clinical Trials Unit as the London Hub for Trials Methodology Research funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1158/1078-0432.ccr-20-3237

PubMed Identifier: 33028592

Publication URI: http://europepmc.org/abstract/MED/33028592

Type: Journal Article/Review

Volume: 27

Parent Publication: Clinical cancer research : an official journal of the American Association for Cancer Research

Issue: 1

ISSN: 1078-0432